Recent news highlights include TScan's quarterly financial results reporting losses and lagging revenue, as well as clinical progress with the initiation of a Phase 3 trial for TSC-101 in hematologic malignancies.

• TScan treated the first patient in a Phase 3 trial of TSC-101 for hematologic malignancies as of July 2026, marking a key clinical development milestone [N2].
• The company reported a Q1 2026 loss and revenue lagging estimates, reflecting ongoing financial challenges [N2].
• TScan reported a Q4 2025 loss and missed revenue estimates, continuing a trend of operating losses [N3].
• An update on the Phase 1 trial of TSC-101 in hematologic malignancies was announced for December 2025, indicating ongoing clinical development [N8].

TScan's proprietary TCR-T platform and ongoing clinical development, including the initiation of a Phase 3 trial for TSC-101 in hematologic malignancies, demonstrate progress toward potential therapeutic innovation in oncology. The company's substantial cash position as of mid-2026 supports continued operations and advancement of its pipeline. Strategic collaborations and licensing agreements provide additional resources and validation of its technology. Successful navigation of manufacturing scale-up and regulatory pathways could enable future commercialization opportunities.

The company faces significant risks including ongoing net losses, substantial capital requirements, and uncertainty regarding the timing and success of clinical development and regulatory approvals. Manufacturing complexity, supply chain dependencies, and potential intellectual property challenges pose operational and competitive risks. Management has disclosed substantial doubt about the company's ability to continue as a going concern beyond the second quarter of 2027 without additional funding. Failure to secure adequate reimbursement or commercial acceptance could further impact prospects. Dilution from future financing and potential loss of licensing rights are additional concerns.

TScan's competitive position is supported by its proprietary T cell receptor technology platform and a portfolio of licensed and internally developed patent applications. The company's focus on TCR-engineered T cell therapies for cancer addresses a specialized and complex therapeutic area requiring advanced manufacturing and development capabilities. However, the patent landscape is uncertain, with risks of challenges, narrow patent scope, and potential competition from alternative technologies. The company's reliance on third-party manufacturing and supply chain partners introduces operational risks. The early stage of product development and absence of commercial products limit current barriers to entry, making intellectual property protection and successful clinical advancement critical to establishing a sustainable competitive advantage.

• Capital and Liquidity Risk: TScan has disclosed substantial doubt about its ability to continue as a going concern beyond the second quarter of 2027 based on current cash and operating plans. The company will require additional funding through equity, debt, or collaborations to continue operations and advance development programs.
• Manufacturing and Supply Chain Risks: The company relies on third-party manufacturers and suppliers for clinical and potential commercial production. Risks include inability to secure manufacturing capacity on acceptable terms, quality control issues, supply disruptions, and regulatory compliance challenges.
• Intellectual Property Risks: Patent protection is critical but uncertain. Patents may be challenged, narrowed, or invalidated. The company depends on licenses that may be terminated or disputed, potentially impairing its rights. Competitors may develop non-infringing alternatives.
• Clinical Development and Regulatory Risks: Product candidates require extensive preclinical and clinical testing and regulatory approvals. Delays, failures, or adverse regulatory decisions could impact development timelines and prospects.
• Operational Risks: The company faces risks related to scaling manufacturing, maintaining chain of identity and custody for patient materials, and managing complex logistics. Cybersecurity risks are addressed but remain a concern.

• TScan Therapeutics, Inc. is a biopharmaceutical company focused on developing T cell receptor (TCR)-engineered T cell (TCR-T) therapies for cancer treatment.
• The company operates a single segment focused on TCR-T therapies.
• TScan relies on third-party manufacturers for clinical trial supply and may use them for commercial manufacturing; manufacturing is complex and requires compliance with FDA cGMP and cGTP regulations.
• The company faces risks related to manufacturing scale-up, quality control, supply chain disruptions, and regulatory compliance.
• TScan's product candidates require specialty materials, some sourced from single or limited suppliers, which may cause supply risks.
• The company has not yet commercialized any product candidates and does not generate product revenue.
• TScan has incurred significant net losses historically and expects to continue incurring losses as it advances development programs.
• As of June 30, 2026, TScan had cash and cash equivalents of $100.2 million and current assets of $104.4 million, with current liabilities of $30.9 million, resulting in a current ratio of 3.37 and a cash ratio of 3.72.
• Net loss for the six months ended June 30, 2026 was $30.4 million with basic and diluted EPS of -$0.23.
• The company has substantial capital requirements related to research, development, clinical trials, regulatory activities, manufacturing, and commercialization preparation.
• TScan has raised capital through equity offerings, debt financings, and collaborations but faces substantial doubt about its ability to continue as a going concern beyond the second quarter of 2027 based on current cash.
• The company holds intellectual property rights including licensed patents and provisional patent applications related to its TCR technology and product candidates.
• Patent protection is critical but uncertain; patents may be challenged, narrowed, or invalidated, and competitors may develop non-infringing alternatives.
• TScan is subject to risks related to intellectual property licensing agreements, including potential termination or disputes that could impair its rights.
• The company recognizes revenue primarily from collaboration and license agreements, notably with Novartis and Amgen, but has not generated product sales revenue.
• Recent clinical development includes advancing TSC-101 in hematologic malignancies, with a Phase 3 trial initiated and first patient treated as of July 2026.
• The company has implemented cybersecurity risk management programs aligned with industry standards.
• Operating expenses are primarily research and development and general and administrative costs, with R&D expenses exceeding $114 million in 2025.
• The company manages operations and performance through its CEO as the chief operating decision maker, focusing on net loss and expense management.
• Recent news reports include quarterly loss announcements and clinical trial progress updates, reflecting ongoing development activities and financial results.